Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024987 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL1641313 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KDM4EATMMETTL3HPGD | |
| SCHEMBL23907305 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL2173552 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL2173551 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL7859358 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL2949847 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1NPC1GLA | |
| SCHEMBL17234569 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1NPC1GLA | |
| Hydrochloric Acid SCHEMBL7526024 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1NPC1GLA | |
| Hydrochloric Acid SCHEMBL7526029 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111705312-A | Chemical tin plating solution and preparation method and application thereof | 信丰正天伟电子科技有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8444774-B2 | Flux composition and process for use thereof | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2521721-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011079778-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
| US-7780801-B2 | for soldering flip chip surfaces; fluxing agent comprises keto acid such as levulinic acid or acetylbutyric acid; mixture of tacky solvent (ethoxylated glycerol) with non-tacky solvent (methanol) | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100175790-A1 | New Flux Composition and Process For Use Thereof | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20080124568-A1 | New flux composition and process for use thereof | GLOBALFOUNDRIES INC. (KY) | 2008-05-29 | — | — | US | disclosed |
| WO-1999031096-A1 | PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS | SHAMAN PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | ALDH1A1 908/4885KDM4E 3742/4885MEN1 2858/4885 |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | ALDH1A1 908/4885KDM4E 3742/4885MEN1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.